U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H7ClN2O2S
Molecular Weight 230.671
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIAZOXIDE

SMILES

CC1=NC2=C(C=C(Cl)C=C2)S(=O)(=O)N1

InChI

InChIKey=GDLBFKVLRPITMI-UHFFFAOYSA-N
InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)

HIDE SMILES / InChI

Molecular Formula C8H7ClN2O2S
Molecular Weight 230.671
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Diazoxide is a drug which was approved by FDA for the treatment of secondary hyperinsulinemia. The drug exerts its action by binding to SUR1 subunit of ATP-sensitive potassium channel that leads to the channel opening.

CNS Activity

Sources: www.ncbi.nlm.nih.gov/pubmed/22056385

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.94 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROGLYCEM

Approved Use

Proglycem (ORAL DIAZOXIDE) is useful in the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy in adults. Infants and Children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis.

Launch Date

2.02089595E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
45 μg/mL
2.5 mg 3 times / day steady-state, oral
dose: 2.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DIAZOXIDE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
345 μg × h/mL
2.5 mg 3 times / day steady-state, oral
dose: 2.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DIAZOXIDE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
30 h
2.5 mg/kg 3 times / day multiple, oral
dose: 2.5 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DIAZOXIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
14.3 h
2.5 mg 3 times / day steady-state, oral
dose: 2.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DIAZOXIDE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
2.5 mg/kg 3 times / day multiple, oral
dose: 2.5 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DIAZOXIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, adult + children
Health Status: unhealthy
Age Group: adult + children
Sources:
Disc. AE: Hyperosmolar (non-ketotic) coma...
AEs leading to
discontinuation/dose reduction:
Hyperosmolar (non-ketotic) coma
Sources:
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, adult
Disc. AE: Diabetic hyperosmolar coma...
AEs leading to
discontinuation/dose reduction:
Diabetic hyperosmolar coma
Sources:
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
Disc. AE: Cataracts...
AEs leading to
discontinuation/dose reduction:
Cataracts
Sources:
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Condition: hypoglycemia hyperinsulinism
Age Group: children
Sources:
Disc. AE: Musculoskeletal and connective tissue deformities of skull, face and buccal cavity...
AEs leading to
discontinuation/dose reduction:
Musculoskeletal and connective tissue deformities of skull, face and buccal cavity (4 patients)
Sources:
15 mg/kg 1 times / day multiple, oral
Dose: 15 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/kg, 1 times / day
Sources:
unhealthy, infant + neonates
Health Status: unhealthy
Age Group: infant + neonates
Sources:
Disc. AE: Pulmonary hypertension...
AEs leading to
discontinuation/dose reduction:
Pulmonary hypertension
Sources:
AEs

AEs

AESignificanceDosePopulation
Hyperosmolar (non-ketotic) coma Disc. AE
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, adult + children
Health Status: unhealthy
Age Group: adult + children
Sources:
Diabetic hyperosmolar coma Disc. AE
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, adult
Cataracts Disc. AE
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
Musculoskeletal and connective tissue deformities of skull, face and buccal cavity 4 patients
Disc. AE
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Condition: hypoglycemia hyperinsulinism
Age Group: children
Sources:
Pulmonary hypertension Disc. AE
15 mg/kg 1 times / day multiple, oral
Dose: 15 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/kg, 1 times / day
Sources:
unhealthy, infant + neonates
Health Status: unhealthy
Age Group: infant + neonates
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
yes
PubMed

PubMed

TitleDatePubMed
Haemodynamic effects of prazosin.
1976 Dec
Cholelithiasis in a newborn following treatment with the somatostatin analogue octreotide.
2000 Jul
Interaction of sulfonylurea-conjugated polymer with insulinoma cell line of MIN6 and its effect on insulin secretion.
2001 Apr
Opening of mitochondrial ATP-sensitive potassium channels enhances cardioplegic protection.
2001 Apr
Glucose and insulin stimulate heparin-releasable lipoprotein lipase activity in mouse islets and INS-1 cells. A potential link between insulin resistance and beta-cell dysfunction.
2001 Apr 13
Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion.
2001 Aug
Involvement of K(ATP) channels in diethylstilbestrol-induced relaxation in rat aorta.
2001 Feb 9
Adenosine A1 receptor activation reduces reactive oxygen species and attenuates stunning in ventricular myocytes.
2001 Jan
Acute hypertension inhibits thirst stimulated by ANG II, hyperosmolality, or hypovolemia in rats.
2001 Jan
Direct activation of mitochondrial K(ATP) channels mimics preconditioning but protein kinase C activation is less effective in middle-aged rat hearts.
2001 Jan
Intrinsic optical signals in respiratory brain stem regions of mice: neurotransmitters, neuromodulators, and metabolic stress.
2001 Jul
Increased calcium vulnerability of senescent cardiac mitochondria: protective role for a mitochondrial potassium channel opener.
2001 Jul 31
Transient hyperinsulinism in an asphyxiated newborn infant with hypoglycemia.
2001 Jun
A novel enhancer of insulinotrophic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta-cells via a new cellular mechanism.
2001 Jun
Characterization of secretory and morphologic properties of primary cultured endocrine cells from porcine pancreata.
2001 Mar
Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia.
2001 Mar
Oxytocin antagonist disrupts hypotension-evoked renin secretion and other responses in conscious rats.
2001 Mar
Chloride channels regulate HIT cell volume but cannot fully account for swelling-induced insulin secretion.
2001 May
Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury.
2001 Oct
Critical timing of mitochondrial K(ATP) channel opening for enhancement of myocardial tolerance against infarction.
2001 Sep
[Activation of ATP-sensitive K+ channels by ADP and K+ channel openers: homology model of sulfonylurea receptor carboxyl-termini].
2001 Sep
Diazoxide induced cardioprotection: what comes first, K(ATP) channels or reactive oxygen species?
2001 Sep
Hepatothermic therapy of obesity: rationale and an inventory of resources.
2001 Sep
Mitochondrial K(ATP) channel activation reduces anoxic injury by restoring mitochondrial membrane potential.
2001 Sep
Identification and pharmacological correction of a membrane trafficking defect associated with a mutation in the sulfonylurea receptor causing familial hyperinsulinism.
2001 Sep 21
Patents

Sample Use Guides

Adults and children: The usual daily dosage is 3 to 8 mg/kg, divided into two or three equal doses every 8 or 12 hours. Infants and newborns: The usual daily dosage is 8 to 15 mg/kg divided into two or three equal doses every 8 to 12 hours. An appropriate starting dosage is 10 mg/kg/day, divided into three equal doses every 8 hours.
Route of Administration: Oral
In Vitro Use Guide
Diazoxide inhibited glucagon secretion in rat pancreas at concentration of 325 uM.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:44:20 UTC 2023
Edited
by admin
on Wed Jul 05 22:44:20 UTC 2023
Record UNII
O5CB12L4FN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIAZOXIDE
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
EUDEMINE INJECTION
Common Name English
DIAZOXIDE [EP MONOGRAPH]
Common Name English
7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
Systematic Name English
DIAZOXIDE [MI]
Common Name English
SCH-6783
Code English
DIAZOXIDE [ORANGE BOOK]
Common Name English
SCH 6783
Code English
Diazoxide [WHO-DD]
Common Name English
HYPERSTAT
Brand Name English
DIAZOXIDE [VANDF]
Common Name English
DIAZOXIDE [USP-RS]
Common Name English
DIAZOXIDE [USP MONOGRAPH]
Common Name English
2H-1,2,4-BENZOTHIADIAZINE, 7-CHLORO-3-METHYL-, 1,1-DIOXIDE
Systematic Name English
HYPERTONALUM
Common Name English
DIAZOXIDE [MART.]
Common Name English
DIAZOXIDE [JAN]
Common Name English
PROGLYCEM
Brand Name English
diazoxide [INN]
Common Name English
DIAZOXIDUM [WHO-IP LATIN]
Common Name English
SRG-95213
Code English
SRG 95213
Code English
NSC-76130
Code English
DIAZOXIDE [WHO-IP]
Common Name English
DIAZOXIDE [USAN]
Common Name English
NSC-64198
Code English
Classification Tree Code System Code
WHO-ATC V03AH01
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
WHO-ATC C02DA01
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
NCI_THESAURUS C29707
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
WHO-VATC QV03AH01
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
WHO-VATC QC02DA01
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
FDA ORPHAN DRUG 383712
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
Code System Code Type Description
MERCK INDEX
M4277
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID7022914
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DIAZOXIDE
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY Description: A white, or almost white, crystalline powder; odourless. Solubility: Practically insoluble in water and ether R; freely soluble in dimethylformamide R; slightly soluble in ethanol (~750 g/l) TS. Category: Antihypertensive. Storage: Diazoxide should be kept in a well-closed container. Definition: Diazoxide contains not less than 98.0% and not more than 101.0% of C8H7ClN2O2S, calculated with reference to thedried substance.
INN
1294
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
ECHA (EC/EINECS)
206-668-1
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
MESH
D003981
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
DRUG BANK
DB01119
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
RXCUI
3327
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY RxNorm
RS_ITEM_NUM
1186000
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
DRUG CENTRAL
854
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
DAILYMED
O5CB12L4FN
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
SMS_ID
100000092606
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
CAS
364-98-7
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
PUBCHEM
3019
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
IUPHAR
2409
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
ChEMBL
CHEMBL181
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
WIKIPEDIA
DIAZOXIDE
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
NSC
64198
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
EVMPD
SUB07071MIG
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
CHEBI
4495
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
NCI_THESAURUS
C428
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
NSC
76130
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
FDA UNII
O5CB12L4FN
Created by admin on Wed Jul 05 22:44:20 UTC 2023 , Edited by admin on Wed Jul 05 22:44:20 UTC 2023
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC